{"id":38581,"date":"2025-08-05T13:22:11","date_gmt":"2025-08-05T05:22:11","guid":{"rendered":"https:\/\/flcube.com\/?p=38581"},"modified":"2025-08-05T13:22:12","modified_gmt":"2025-08-05T05:22:12","slug":"kexing-partners-with-guangdong-zhongsheng-to-commercialize-onradivir-tablets-in-macau","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38581","title":{"rendered":"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau"},"content":{"rendered":"\n

On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136<\/a>) announced a partnership with Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317<\/a>) to commercialize onradivir tablets in Macau, China. This collaboration marks a significant step in the commercialization of this innovative antiviral medication.<\/p>\n\n\n\n

About Onradivir<\/strong>
Onradivir is the world’s first influenza RNA polymerase PB2 protein inhibitor. It was independently developed by Guangdong Raynovent Biotech Co., Ltd., a subsidiary of Zhongsheng Pharmaceutical. The drug received marketing approval from China’s National Medical Products Administration (NMPA) in May 2025 for the treatment of uncomplicated influenza A in adults.<\/p>\n\n\n\n

Commercialization Efforts<\/strong>
Through this partnership, Kexing Biopharm and Guangdong Zhongsheng aim to leverage their combined expertise to successfully introduce onradivir tablets to the Macau market. This initiative underscores their commitment to providing innovative treatment options for influenza patients.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with…<\/p>\n","protected":false},"author":1,"featured_media":38585,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3625,1229,1197,399],"class_list":["post-38581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-kexing-biopharm","tag-sha-688136","tag-she-002317","tag-zhongsheng-pharmaceutical"],"yoast_head":"\nKexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) to commercialize onradivir tablets in Macau, China. This collaboration marks a significant step in the commercialization of this innovative antiviral medication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38581\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau\" \/>\n<meta property=\"og:description\" content=\"On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) to commercialize onradivir tablets in Macau, China. This collaboration marks a significant step in the commercialization of this innovative antiviral medication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38581\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-05T05:22:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-05T05:22:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau\",\"datePublished\":\"2025-08-05T05:22:11+00:00\",\"dateModified\":\"2025-08-05T05:22:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581\"},\"wordCount\":145,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0502.webp\",\"keywords\":[\"Kexing Biopharm\",\"SHA: 688136\",\"SHE: 002317\",\"Zhongsheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38581#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38581\",\"name\":\"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0502.webp\",\"datePublished\":\"2025-08-05T05:22:11+00:00\",\"dateModified\":\"2025-08-05T05:22:12+00:00\",\"description\":\"On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) to commercialize onradivir tablets in Macau, China. This collaboration marks a significant step in the commercialization of this innovative antiviral medication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38581\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38581#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau - Insight, China's Pharmaceutical Industry","description":"On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) to commercialize onradivir tablets in Macau, China. This collaboration marks a significant step in the commercialization of this innovative antiviral medication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38581","og_locale":"en_US","og_type":"article","og_title":"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau","og_description":"On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) to commercialize onradivir tablets in Macau, China. This collaboration marks a significant step in the commercialization of this innovative antiviral medication.","og_url":"https:\/\/flcube.com\/?p=38581","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-05T05:22:11+00:00","article_modified_time":"2025-08-05T05:22:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38581#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38581"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau","datePublished":"2025-08-05T05:22:11+00:00","dateModified":"2025-08-05T05:22:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38581"},"wordCount":145,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38581#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0502.webp","keywords":["Kexing Biopharm","SHA: 688136","SHE: 002317","Zhongsheng Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38581#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38581","url":"https:\/\/flcube.com\/?p=38581","name":"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38581#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38581#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0502.webp","datePublished":"2025-08-05T05:22:11+00:00","dateModified":"2025-08-05T05:22:12+00:00","description":"On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) to commercialize onradivir tablets in Macau, China. This collaboration marks a significant step in the commercialization of this innovative antiviral medication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38581#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38581"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38581#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0502.webp","width":1080,"height":608,"caption":"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38581#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38581"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38581\/revisions"}],"predecessor-version":[{"id":38586,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38581\/revisions\/38586"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38585"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}